Nyxoah S.A. (NYXH) Cash Flow Statement

The persistent gap between net income and operating cash flow indicates that the company is not generating sufficient internal liquidity to cover its operational footprint. Investors should monitor whether this divergence narrows as the company attempts to scale, as current figures suggest a reliance on external funding to bridge the gap between accounting losses and actual cash outflows.

The trajectory of free cash flow reflects a business model that is currently in a heavy investment phase with no immediate path to self-sustainability. The lack of positive FCF margins suggests that the company's current scale is insufficient to absorb the high fixed costs associated with its R&D and regulatory requirements.

These fluctuations in working capital suggest that the company's cash conversion cycle is not yet optimized, likely due to the complexities of managing a specialized medical device supply chain. Analysts should investigate whether these swings are indicative of seasonal stocking patterns or broader inefficiencies in the company's accounts receivable and inventory processes.

The high capital intensity relative to revenue suggests that the company is still in the process of building out its core operational infrastructure. This level of spending warrants further investigation to determine if these costs are primarily maintenance-related or if they represent ongoing growth investments that will eventually taper off as the company achieves greater manufacturing scale.